Clinical Study

QTc Prolongation in Patients Acutely Admitted to Hospital for Psychosis and Treated with Second Generation Antipsychotics

Erik Johnsen,1,2 Kristina Aanesen,1 Sanjeevan Sriskandarajah,3 Rune A. Kroken,1 Else-Marie Løberg,1,4 and Hugo A. Jørgensen2

1 Division of Psychiatry, Haukeland University Hospital, Sandviken, Norway
2 Department of Clinical Medicine, Section Psychiatry, University of Bergen, Norway
3 Faculty of Medicine and Dentistry, University of Bergen, Norway
4 Department of Biological and Medical Psychology, University of Bergen, Norway

Correspondence should be addressed to Erik Johnsen; erik.johnsen@helse-bergen.no

Received 31 July 2013; Accepted 21 November 2013

Academic Editor: Sonia Dollfus

Copyright © 2013 Erik Johnsen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

QTc interval prolongation is a side effect of several antipsychotic drugs, with associated risks of torsade de pointes arrhythmias and sudden cardiac death. There is an ongoing debate of whether or not electrocardiogram (ECG) assessments should be mandatory in patients starting antipsychotic drugs. To investigate QTc prolongation in a clinically relevant patient group 171 adult patients acutely admitted to an emergency ward for psychosis were consecutively recruited. ECGs were recorded at baseline and then at discharge or after 6 weeks at the latest (discharge/6 weeks), thus reflecting the acute phase treatment period. The mean QTc interval was 421.1 (30.4) ms at baseline and there was a positive association between the QTc interval and the agitation score whereas the QTc interval was inversely associated with the serum calcium level. A total of 11.6% had abnormally prolonged QTc intervals and another 14.3% had borderline prolongation. At discharge/6 weeks, the corresponding proportions were reduced to 4.2% and 5.3%, respectively. The reduction of the proportion with prolonged QTc intervals reached statistical significance (chi-square exact test: $P = 0.046$). The finding of about one-quarter of the patients with borderline or prolonged QTc intervals could indicate mandatory ECG recordings in this population. This trial is registered with ClinicalTrials.gov ID: NCT00932529.

1. Introduction

Prolongation of the heart rate-corrected QT (QTc) interval of the electrocardiogram (ECG) is a major concern because of the associated risk of torsade de pointes (TdP) arrhythmias and sudden cardiac death [1]. QTc intervals longer than 500 milliseconds (ms) or increases of more than 60 ms of the QTc interval are established thresholds for clear concern of arrhythmia but increased risk is found also at lower levels of QTc prolongation [2]. The QT interval represents the onset of electrical depolarisation of the ventricles to the end of repolarisation of the heart [1, 2] and is influenced by both physiological and pathological factors including emotional stress, gender, obesity, food consumption, and electrolyte disturbances, as well as diseases of the heart muscle and coronary artery disease [2–4]. Moreover, several drugs including psychotropics can induce prolongation of the QTc interval principally by blocking the rapidly activating potassium current [2, 5, 6]. Antipsychotic drugs are associated with dose related QTc prolongation, and some agents have been intermittently or permanently withdrawn from the market for this reason [2, 5, 7]. Treatment recommendations for schizophrenia differ substantially, however, with regard to whether or not ECG recordings should be routinely undertaken in all patients starting antipsychotic drug treatment [8–12]. Some recommend ECG recordings in patients considered at increased risk from QTc prolongation only [8–10], whereas others recommend mandatory ECG in all patients [11], or in those admitted to hospital [12]. Importantly, patients with schizophrenia may have a heightened background risk for QTc prolongation irrespective of the drug effects, as recent studies report considerably increased prevalence of cardiovascular disease (CVD) in schizophrenia [13, 14] and that CVD is suboptimally addressed in this population.
Patients acutely admitted to hospital. All eligible patients met the patient inclusion criteria and were included in the study. Consent was provided, thus entailing a clinically relevant sample. Studies in selected samples could bias the results. Together, acute admission to hospital may represent a particular risk situation for QTc prolongation in schizophrenic patients. To the best knowledge of the authors, studies investigating the QTc interval in samples representative of acutely admitted patients with psychosis are scarce as patients with, for example, illicit drug abuse and somatic disease are typically excluded in antipsychotic drug studies.

The primary aims of the study were to investigate the proportions with prolonged QTc interval at hospital admission and discharge or at 6 weeks from baseline at the latest, if not discharged earlier (discharge/6 weeks). Secondary aims were to assess the influence of electrolyte levels and emotional stress at baseline and antipsychotic drug use at discharge/6 weeks on the QTc interval. The patient recruitment focused on all patients with psychosis acutely admitted to the emergency ward to ensure a clinically relevant sample.

2. Materials and Methods

The materials and methods used have been described in greater detail elsewhere [20]. The study is part of a pragmatic, randomized trial comparing second generation antipsychotics (SGAs) in the treatment of psychosis including 226 patients. The present paper reports data obtained at baseline and discharge/6 weeks in patients who underwent ECG recordings. Patients were consecutively recruited from March 2004 until February 2009 from the Haukeland University Hospital with a catchment population of about 400,000. The study was approved by the Regional Committee for Medical Research Ethics and the Norwegian Social Science Data Services. The study was publicly funded and has not received any financial or other support from the pharmaceutical industry. The Regional Committee for Medical Research Ethics allowed eligible patients to be included before informed consent was provided, thus entailing a clinically relevant representation in the study. All adult patients were eligible for the study if they were acutely admitted to the emergency ward for symptoms of active psychosis as determined by a score of ≥4 on one or more of the items delusions, hallucinatory behavior, grandiosity, suspiciousness/persecution, or unusual thought content in the PANSS [21] and were candidates for oral antipsychotic drug therapy. Accordingly, the patient inclusion encompassed the consecutive recruitment of a clinically representative sample of psychosis patients acutely admitted to hospital. All eligible patients met the ICD-10 diagnostic criteria (http://apps.who.int/classifications/icd10/browse/2010/en) for schizophrenia, schizoaffective disorder, acute and transient psychotic disorder, delusional disorder, drug-induced psychosis, bipolar disorder except for manic psychosis, or major depressive disorder with psychotic features. The diagnoses were determined by the hospital’s psychiatrists or specialists in clinical psychology. Patients were excluded from the study if they were unable to use oral antipsychotics, were suffering from manic psychosis, or for other behavioral or mental reasons related to the state of illness were unable to cooperate with assessments, did not understand spoken Norwegian, were candidates for electroconvulsive therapy, or were medicated with clozapine on admittance. Patients with drug-induced psychoses were included only when the condition did not resolve within a few days and when antipsychotic drug therapy was indicated.

2.1. Assessments. Assessments were conducted at baseline and discharge/6 weeks. Before inclusion, eligible patients underwent the PANSS structured clinical interview. Intraclass correlation coefficients (ICC) were calculated based on interrater assessments and showed high interrater reliability (0.92). The PANSS excited component (PANSS-EC), consisting of the PANSS items P4 (excitement), P7 (hostility), G4 (tension), G8 (uncooperativeness), and G14 (poor impulse control) as validated by Montoya et al. [22], was used as a proxy for emotional stress. Furthermore, the Calgary Depression Scale for Schizophrenia (CDSS) [23] and the Clinical Drug and Alcohol Use Scales (CDUS/CAUS) [24] were used, as well as a neurocognitive test battery [25], and the patients were rated according to the Clinical Global Impression—Severity of Illness scale (CGI-S) [26], and the Global Assessment of Functioning—Split Version, Functions scale (GAF-F) [27]. A blood sample was collected from the patients between 08 and 10 a.m. for analyses of serum potassium, sodium and calcium, and serum level measurements of antipsychotics at discharge/6 weeks.

Drug doses were converted to mean defined daily doses (DDDs) as developed by the World Health Organization Collaborating Centre for Drug Statistics Methodology [20]. The basic definition of the DDD unit is the assumed average maintenance dose per day for a drug used for its main indication in adults.

2.2. QTc Assessments. The QTc interval estimation was done automatically by a Philips Pagewriter Trim II cardiograph at admission and discharge/6 weeks. Bazett’s formula was used for correction. The ECG recording at baseline was done before the first administration of the study SGAs. The QTc ratings were for each gender divided into normal, borderline, and prolonged groups according to the Committee for Proprietary Medicinal Products (http://www.fda.gov/ohrms/dockets/ac/03/briefing/pubs/cpmp.pdf). The cutoff points were for men less than 430 milliseconds (ms) (normal), 430 to 450 ms (borderline), and more than 450 ms (prolonged) and for women less than
450 ms (normal), 450–470 ms (borderline), and more than 470 ms (prolonged).

2.3. Statistical Procedures. Categorical and continuous data at baseline and at discharge/6 weeks, respectively, were analyzed by means of exact $\chi^2$-tests, independent samples $t$-tests, and one-way ANOVAs by using the SPSS software, version 20.0 (IBM SPSS Statistics, 2011). For comparing mean QTc intervals at baseline and at discharge/6 weeks, paired-sample $t$-tests were used. To investigate the association between QTc intervals and the levels of individual electrolytes, as well as the PANSS-EC, a bivariate analysis of correlation was performed using the Pearson correlation coefficient as normal distribution was assumed. These variables were also analysed collectively by means of linear regression. The level of statistical significance was set at $\alpha = 0.05$, two-sided.

3. Results

A total of 171 patients (75.7% of the total sample) underwent ECG recordings on at least one of the time points. In the patients without ECG recordings the principal reasons were refusal or inability to cooperate with the measurements. Baseline clinical and demographic characteristics are displayed in Table 1, and there were no differences between those with and without ECG recordings. Those without ECG recordings had a numerically higher mean PANSS-EC score compared to those with ECG recordings but the difference did not reach statistical significance (independent samples $t$-test, equal variances assumed: $P = 0.126$; mean difference 0.72; 95% confidence interval (CI) $-0.20–1.64$).

The mean QTc interval was 421.1 (30.4) ms at baseline, and 11.6% of the patients had abnormally prolonged QTc (Figure 1). Another 14.3% had borderline QTc intervals. Two patients had QTc intervals above 500 ms.

There were no statistical differences among the genders or among the drug naïve and those with prior antipsychotic drug exposure with regard to mean QTc interval or proportion with QTc prolongation. Mean serum levels with standard deviations (SD) and reference ranges in brackets of sodium, potassium, and calcium were 141.3 (2.3) (137.0–145.0), 4.3 (0.4) (3.5–5.0), and 2.4 (0.1) (2.2–2.6) nanomoles per litre, respectively. There was a statistically significant negative association between QTc interval and serum calcium level (Pearson correlation: $r = -0.186$, $P = 0.027$), whereas no association was found between the QTc interval and sodium or potassium, respectively. There was a positive association between the PANSS-EC and the QTc interval (Pearson correlation: $r = 0.170$, $P = 0.040$). When the electrolytes and the PANSS-EC were entered as independent variables into a linear regression model with the QTc interval as the dependent variable the association between serum calcium and the QTc interval remained unaltered whereas the correlation between the PANSS-EC and the QTc interval increased (Pearson correlation: $r = 0.205$, $P = 0.008$).

A total of 95 patients were reassessed at discharge/6 weeks. Three of these patients were for practical reasons tested later than 6 weeks, at weeks 7, 10, and 11, respectively, but are included in the analyses. There were no significant differences between those tested only at baseline and those tested also at discharge/6 weeks with regard to baseline mean QTc interval or proportions with borderline or prolonged QTc intervals, neither were there baseline clinical or demographic differences. The mean QTc at discharge/6 weeks was 411.3 (23.1) ms. The proportions with prolonged or borderline QTc recordings were reduced to 4.2% and 5.3%, respectively (Figure 2).

One patient had QTc interval > 500 ms and 4 patients had their QTc intervals increased more than 60 ms from

---

**Table 1: Baseline demographics and clinical characteristics.**

| Characteristics | N  | % of sample |
|-----------------|----|-------------|
| Gender          |    |             |
| Male            | 118| 69.0        |
| Female          | 53 | 31.0        |
| Antipsychotic drug naïve | 73 | 42.7 |
| Alcohol use last 6 months |    |             |
| None            | 33 | 19.3        |
| Misuse          | 12 | 7.0         |
| Illicit drug use last 6 months |    |             |
| None            | 118| 69.0        |
| Misuse          | 29 | 17.0        |
| Diagnosis       |    |             |
| Schz and related | 95 | 57.5 |
| Acute           | 13 | 7.9         |
| Drug-induced    | 21 | 12.7        |
| Affective       | 19 | 11.5        |
| Rest            | 17 | 10.2        |

Notes. $N$ = number of patients with ECG at baseline and/or ECG at discharge; SD = standard deviation; antipsychotic drug naïve = no life-time exposure to antipsychotic drugs before index admission; first admission = index admission was the first admission to a mental hospital; misuse = misuse or dependence according to the Clinical Drug and Alcohol Use Scales (CDUS/CAUS); patients with no illicit drug use could be included in the category alcohol use last 6 months; Schz and related = schizophrenia and related disorders: schizophrenia, schizoaffective disorder, acute polymorphic psychotic disorder with symptoms of schizophrenia, acute schizophrenia-like psychotic disorder, and delusional disorder; acute = acute psychosis other than those categorized under Schz and related; affective = affective psychoses; rest = miscellaneous psychotic disorders. All diagnoses are according to ICD-10; PANSS = the positive and negative syndrome scale; CDSS = the Calgary Depression Scale for Schizophrenia; GAF-F = the Global Assessment of Functioning—Split Version. Functions scale; CGI = the Clinical Global Impression. Severity of Illness scale; RBANS = the repeatable battery for the assessment of neuropsychological status.

1 Patients with missing diagnoses are not included in the list.
baseline. The reduction of the proportion with prolonged QTc levels reached statistical significance (chi-square exact test: \( P = 0.046 \)). There was a trend only for the reduction of the mean QTc (paired-samples \( t \)-test: \( P = 0.063 \); mean difference 7.5 ms; 95% CI –0.4–15.4). The use of antipsychotic drugs is displayed in Table 2. Two patients did not use antipsychotics at discharge/6 weeks.

The mean DDD with SD was 1.02 (0.55). There were no differences among the drug groups with respect to mean QTc interval or proportions with QTc prolongation. Concomitant antidepressants and/or mood stabilizers (lithium and anticonvulsants) and/or sporadic additional antipsychotics were used by 35.2%, 8.5%, and 18.3%, respectively, at discharge/6 weeks. There were no differences among the antipsychotic drug groups in this regard. There was no association between QTc level and DDD, or serum levels, respectively, of the antipsychotic drugs.

4. Discussion

The main findings of the present study in acutely admitted patients with psychosis were that almost a quarter of the patients had prolonged or borderline prolonged QTc intervals at hospital admission and this proportion was significantly reduced at discharge/6 weeks after the initiation of antipsychotic drug treatment with SGAs. Moreover, 2 patients at baseline and 1 patient at discharge/6 weeks had QTc intervals above the critical threshold of 500 ms, and 4 patients had their QTc intervals increased by more than 60 ms between baseline and discharge/6 weeks. The findings underscore that the acute admission situation may represent a particular risk phase with regard to QTc prolongation in this patient group. The baseline ECG recording was done before administration of the study drugs and although about half the sample had lifetime antipsychotic drug exposure it is reasonable to assume that only a minority had used their antipsychotics according to the prescription in the last period of time before admittance [28]. The high proportion with QTc prolongation at baseline must accordingly be explained also by factors other than the antipsychotic drugs. The reduced proportion with QTc prolongation at discharge/6 weeks further underscores this interpretation as one would expect that at least some of the SGAs under investigation should drive the QTc interval towards prolongation [2]. The results thus may suggest that in heterogeneous sample such as ours of acutely admitted psychosis patients the relative impacts on the QTc interval by antipsychotic drugs are outweighed by other factors including emotional stress.

Although the mean electrolyte levels were all within the reference ranges, there was a statistically significant negative association between serum calcium levels and the QTc intervals at baseline. Hypocalcemia has been shown to cause prolongation of the QTc interval [2, 4], and our results indicate that the association is present also within the reference range. Serum calcium levels in the lower end of the reference interval might accordingly represent an independent risk factor for QTc prolongation. By using the PANSS-EC as a proxy for emotional distress, we found a positive association between the agitation score and the QTc interval in the linear regression model. The study thus supports the findings indicated by Hatta et al. [18] that emotional distress may increase the QTc interval, contributing to the increased
The results may indicate that ECG recordings should be mandatory in acutely admitted patients with psychosis to detect those at heightened risk of arrhythmias.

Conflict of Interests

Erik Johnsen has received honoraria for lectures given in meetings arranged by Bristol-Myers Squibb, Eli Lilly, and AstraZeneca and for a contribution to an information brochure by Eli Lilly. Erik Johnsen has been reimbursed by the Eli Lilly company and the Janssen-Cilag company for attending conferences. Rune Kroken has been reimbursed by the Eli Lilly company, the Janssen-Cilag company, Bristol-Myers Squibb, and AstraZeneca for attending conferences.
Hugo A. Jørgensen has been reimbursed by the Eli Lilly company for a contribution to an information brochure. Kristina Aanesen, Sanjeevaan Sriskandarajah, and Else-Marie Löberg declare no conflict of interests regarding the publication of this paper.

Acknowledgments

This work was supported by the Research Council of Norway, the Western Norway Regional Health Authority, and Haukeland University Hospital. The funding source had no role in the study design; in collection, analyses, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

References

[1] A. H. Glassman and J. T. Bigger Jr., “Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death,” American Journal of Psychiatry, vol. 158, no. 11, pp. 1774–1782, 2001.

[2] P. M. Haddad and I. M. Anderson, “Antipsychotic-related QTc prolongation, torsade de pointes and sudden death,” Drugs, vol. 62, no. 11, pp. 1649–1671, 2002.

[3] C. van Noord, M. Eijgelsheim, and B. H. C. Stricker, “Drug- and non-drug-associated QT interval prolongation,” British Journal of Clinical Pharmacology, vol. 70, no. 1, pp. 16–23, 2010.

[4] N. El-Sherif and G. Turitto, “Electrolyte disorders and arrhythmogenesis,” Cardiology Journal, vol. 18, no. 3, pp. 233–245, 2011.

[5] J. Nielsen, C. Graff, J. K. Kanters, E. Toft, D. Taylor, and J. M. Meyer, “Assessing QT interval prolongation and its associated risks with antipsychotics,” CNS Drugs, vol. 25, no. 6, pp. 473–490, 2011.

[6] S. R. Beach, C. M. Celano, P. A. Noseworthy, J. L. Januzzi, and J. C. Huffman, “QTc prolongation, torsades de pointes, and psychotrophic medications,” Psychosomatics, vol. 54, no. 1, pp. 1–13, 2013.

[7] E. Lindström, L. Farde, J. Eberhard, and W. Haverkamp, “QTc interval prolongation and antipsychotic drug treatments: focus on sertrindole,” International Journal of Neuropsychopharmacology, vol. 9, no. 4, pp. 615–629, 2005.

[8] D. A. Addington, R. H. Bouchard, J. Goldberg et al., “Clinical practice guidelines. Treatment of Schizophrenia,” Canadian Journal of Psychiatry, vol. 50, supplement 1, 2005.

[9] T. R. Barnes, “Evidence-based guidelines for the pharmacological treatment of Schizophrenia: recommendations from the British Association for Psychopharmacology,” Journal of Psychopharmacology, vol. 25, no. 5, pp. 567–620, 2011.

[10] A. F. Lehman, J. A. Lieberman, L. B. Dixon et al., “Practice guideline for the treatment of patients with Schizophrenia, second edition,” American Journal of Psychiatry, vol. 161, no. 2, p. 1-56, 2004.

[11] A. M. Dons, Vejledning Om Behandling Med Antipsykotiske Lagemidler Til Patienter Over 18 År, Sundhedsstyrelsen, Copenhagen, Denmark, 2007.

[12] National Institute for Clinical Excellence (NICE), “The NICE Guideline on core interventions in the treatment and management of Schizophrenia in adults in primary and secondary care—updated edition,” in National Institute for Clinical Excellence, London, UK, 2009, http://guidance.nice.org.uk/CG82/Guidance/pdf/English.

[13] M. Lahti, J. Tiihonen, H. Wildgust et al., “Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia,” Psychological Medicine, vol. 42, no. 11, pp. 2275–2285, 2012.

[14] M. De Hert, J. M. Dekker, D. Wood, K. G. Kahl, R. I. G. Holt, and H.-J. Möller, “Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC),” European Psychiatry, vol. 24, no. 6, pp. 412–424, 2009.

[15] D. P. J. Osborn, G. Baio, K. Walters et al., “Inequalities in the provision of cardiovascular screening to people with severe mental illnesses in primary care. Cohort study in the United Kingdom THIN Primary Care Database 2000–2007,” Schizophrenia Research, vol. 129, no. 2-3, pp. 104–110, 2011.

[16] E. Johnsen, R. Gjestad, R. A. Krogen, L. Mellesdal, E.-M. Löberg, and H. A. Jørgensen, “Cardiovascular risk in patients admitted for psychosis compared with findings from a population-based study,” Nordic Journal of Psychiatry, vol. 65, no. 3, pp. 192–202, 2011.

[17] K.-J. Bär, M. Koschke, M. K. Boettiger et al., “Acute psychosis leads to increased QT variability in patients suffering from Schizophrenia,” Schizophrenia Research, vol. 95, no. 1–3, pp. 115–123, 2007.

[18] K. Hatta, T. Takahashi, H. Nakamura, H. Yamashiro, and Y. Yonezawa, “Prolonged QT interval in acute psychotic patients,” Psychiatry Research, vol. 94, no. 3, pp. 279–285, 2000.

[19] S. Leucht, S. Heres, J. Hamann, and J. M. Kane, “Methodological issues in current antipsychotic drug trials,” Schizophrenia Bulletin, vol. 34, no. 2, pp. 275–285, 2008.

[20] E. Johnsen, R. A. Krogen, T. Wentzel-Larsen, and H. A. Jørgensen, “Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone,” BMC Psychiatry, vol. 10, article 26, 2010.

[21] S. R. Kay, A. Fiszbein, and L. A. Opler, “The positive and negative syndrome scale (PANSS) for Schizophrenia,” Schizophrenia Bulletin, vol. 13, no. 2, pp. 261–276, 1987.

[22] A. Montoya, A. Valladares, L. Lizán, L. San, R. Escobar, and S. Paz, “Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room,” Health and Quality of Life Outcomes, vol. 9, article 18, 2011.

[23] D. Addington, J. Addington, and B. Schissel, “A depression rating scale for schizophrenics,” Schizophrenia Research, vol. 3, no. 4, pp. 247–251, 1990.

[24] R. E. Drake, S. D. Rosenberg, and K. T. Mueser, “Assessing substance use disorder in persons with severe mental illness,” New Directions for Mental Health Services, no. 70, pp. 3–17, 1996.

[25] C. Randolph, M. C. Tierney, E. Mohr, and T. N. Chase, “The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity,” Journal of Clinical and Experimental Neuropsychology, vol. 20, no. 3, pp. 310–319, 1998.

[26] W. Guy, Assessment Manual for Psychopharmacology—Revised, Vol. DHIHS Publ NO ADM 91-338, US Department of Health and Human Services, Rockville, Md, USA, 1976.

[27] S. P. Karterud, G. Pedersen, H. Loevdahl, and S. Friis, Global Assessment of Functioning—Split Version (S-GAF): Background
and Scoring Manual, Ullevaal University Hospital, Department of Psychiatry, Oslo, Norway, 1998.

[28] S. Leucht and S. Heres, “Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in Schizophrenia,” Journal of Clinical Psychiatry, vol. 67, supplement 5, pp. 3–8, 2006.

[29] B. Darpo, M. Agin, D. J. Kazierad et al., “Man versus machine: is there an optimal method for QT measurements in thorough QT studies?” Journal of Clinical Pharmacology, vol. 46, no. 6, pp. 598–612, 2006.